FirstWave Capital Management LLC Purchases 66,972 Shares of TransMedics Group, Inc. $TMDX

FirstWave Capital Management LLC raised its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 53.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 191,240 shares of the company’s stock after acquiring an additional 66,972 shares during the period. TransMedics Group makes up 5.6% of FirstWave Capital Management LLC’s investment portfolio, making the stock its 3rd largest holding. FirstWave Capital Management LLC’s holdings in TransMedics Group were worth $12,702,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in TMDX. Silvant Capital Management LLC acquired a new position in shares of TransMedics Group during the second quarter worth about $26,000. Harvest Fund Management Co. Ltd purchased a new stake in TransMedics Group in the 3rd quarter valued at approximately $29,000. North Star Investment Management Corp. purchased a new stake in TransMedics Group in the 1st quarter valued at approximately $30,000. Ascentis Independent Advisors acquired a new position in TransMedics Group during the 1st quarter worth approximately $30,000. Finally, Allworth Financial LP increased its position in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently commented on the company. Piper Sandler reissued an “overweight” rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. TD Cowen reissued a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a report on Wednesday, July 1st. Finally, Canaccord Genuity Group restated a “buy” rating and set a $124.00 target price on shares of TransMedics Group in a research report on Tuesday, June 30th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, TransMedics Group has a consensus rating of “Hold” and a consensus price target of $124.18.

TransMedics Group Price Performance

TMDX stock opened at $89.98 on Friday. The stock’s 50 day moving average price is $80.14 and its 200 day moving average price is $92.21. The firm has a market cap of $3.11 billion, a P/E ratio of 23.13 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.92 earnings per share. On average, sell-side analysts expect that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.